SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Pluvia's Fist.com - Pluvia's Plays & Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: Pluvia who wrote (977)9/12/2000 2:42:51 PM
From: semi_infinite   Read Replies (1) | Respond to of 1766
 
2 questions on trms:
1. why did Roche fund manufacturing facilities despite the uncertainties?
2. why would the FDA let trms proceed with phase III without clarifying the phase II issues that you described?



To: Pluvia who wrote (977)9/12/2000 11:57:08 PM
From: Valueman  Read Replies (1) | Respond to of 1766
 
7. Patients in both studies had failed previous anti-HIV treatment due to drug resistance. So both Durant and the T-20 study used the same type of patient.

Even a cursory examination of the two trials shows that the population of patients were significantly different in their level of previous exposure to ARVs, number of mutations, CD4 counts, etc. Your comparison of the two trials is flawed.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News